STOCK TITAN

Motus GI Scheduled to Participate in the Piper Sandler 32nd Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

FORT LAUDERDALE, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to participate in the Piper Sandler 32nd Annual Healthcare Conference, which is scheduled to take place virtually from December 1-3, 2020.

Tim Moran, Chief Executive Officer of Motus GI, will participate in a fireside chat that will be available via webcast on the Piper Sandler conference site (click here) from November 25th to December 3rd, and on the Events page on the Company’s website, www.motusgi.com. An archive of the webcast will continue to be available on the Company’s website for 90 days.

In addition, the Motus GI management team will be participating in 1x1 meetings on December 2, 2020, meetings may be requested exclusively via Piper Sandler.

About Motus GI

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.

Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com


MOTUS GI HOLDINGS INC

OTC:MOTS

MOTS Rankings

MOTS Latest News

MOTS Stock Data

435.11k
4.97M
1.12%
4.71%
0.45%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
FT. LAUDERDALE

About MOTS

motus gi holdings, inc. (nasdaq: mots) is a medical technology company based in the u.s., with subsidiaries in the u.s. and israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. the company is focused on the development and commercialization of the pure-vu® system, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. the pure-vu® system is a 510(k) u.s. food and drug administration cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. the device integrates with standard colonoscopes to enable cleaning during the procedure while preserving standard procedural workflow and techniques. the pure-vu® system has received ce mark approval in europe.